



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

NOTICE OF ALLOWANCE AND FEE(S) DUE

81177 7590 09/24/2024
Cleveland Medical Devices Inc.
4415 Euclid Ave. Ste. 500
Cleveland, OH 44103

EXAMINER

NATNITHADHA, NAVIN

ART UNIT

PAPER NUMBER

3791

DATE MAILED: 09/24/2024

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
18/510,801	11/16/2023	Hani Kayyali	CMD-135	8871

TITLE OF INVENTION: Devices and Methods for Sleep Disorder Diagnosis and Treatment

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	SMALL	\$480	\$0.00	\$0.00	\$480	12/24/2024

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

HOW TO REPLY TO THIS NOTICE:

I. Review the ENTITY STATUS shown above. If the ENTITY STATUS is shown as SMALL or MICRO, verify whether entitlement to that entity status still applies.

If the ENTITY STATUS is the same as shown above, pay the TOTAL FEE(S) DUE shown above.

If the ENTITY STATUS is changed from that shown above, on PART B - FEE(S) TRANSMITTAL, complete section number 5 titled "Change in Entity Status (from status indicated above)".

For purposes of this notice, small entity fees are 40% the amount of undiscounted fees, and micro entity fees are 20% the amount of undiscounted fees.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Maintenance fees are due in utility patents issuing on applications filed on or after Dec. 12, 1980. It is patentee's responsibility to ensure timely payment of maintenance fees when due. More information is available at www.uspto.gov/PatentMaintenanceFees.

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), by mail or fax, or via the USPTO patent electronic filing system.

By mail, send to: Mail Stop ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

By fax, send to: (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications. **Because electronic patent issuance may occur shortly after issue fee payment, any desired continuing application should preferably be filed prior to payment of this issue fee in order not to jeopardize copendency.**

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

81177 7590 09/24/2024
Cleveland Medical Devices Inc.
4415 Euclid Ave. Ste. 500
Cleveland, OH 44103

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being transmitted to the USPTO via the USPTO patent electronic filing system or by facsimile to (571) 273-2885, on the date below.

_____ (Typed or printed name)
_____ (Signature)
_____ (Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
18/510,801	11/16/2023	Hani Kayyali	CMD-135	8871

TITLE OF INVENTION: Devices and Methods for Sleep Disorder Diagnosis and Treatment

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	SMALL	\$480	\$0.00	\$0.00	\$480	12/24/2024

EXAMINER	ART UNIT	CLASS-SUBCLASS
NATNITHITHADHA, NAVIN	3791	128-204230

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).

- ☐ Change of correspondence address (or Change of Correspondence Address form PTO/AIA/122 or PTO/SB/122) attached.
- ☐ "Fee Address" indication (or "Fee Address" Indication form PTO/AIA/47 or PTO/SB/47; Rev 03-02 or more recent) attached. **Use of a Customer Number is required.**

2. For printing on the patent front page, list

- (1) The names of up to 3 registered patent attorneys or agents OR, alternatively, 1 _____
- (2) The name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed. 2 _____
- 3 _____

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document must have been previously recorded, or filed for recordation, as set forth in 37 CFR 3.11 and 37 CFR 3.81(a). Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE

(B) RESIDENCE: (CITY and STATE OR COUNTRY)

Please check the appropriate assignee category or categories (will not be printed on the patent) : ☐ Individual ☐ Corporation or other private group entity ☐ Government

4a. Fees submitted: ☐ Issue Fee ☐ Publication Fee (if required)

4b. Method of Payment: (Please first reapply any previously paid fee shown above)

- ☐ Electronic Payment via the USPTO patent electronic filing system ☐ Enclosed check ☐ Non-electronic payment by credit card (Attach form PTO-2038)
- ☐ The Director is hereby authorized to charge the required fee(s), any deficiency, or credit any overpayment to Deposit Account No. _____

5. Change in Entity Status (from status indicated above)

- ☐ Applicant certifying micro entity status. See 37 CFR 1.29
- ☐ Applicant asserting small entity status. See 37 CFR 1.27
- ☐ Applicant changing to regular undiscounted fee status.

NOTE: Absent a valid certification of Micro Entity Status (see forms PTO/SB/15A and 15B), issue fee payment in the micro entity amount will not be accepted at the risk of application abandonment.

NOTE: If the application was previously under micro entity status, checking this box will be taken to be a notification of loss of entitlement to micro entity status.

NOTE: Checking this box will be taken to be a notification of loss of entitlement to small or micro entity status, as applicable.

NOTE: This form must be signed in accordance with 37 CFR 1.31 and 1.33. See 37 CFR 1.4 for signature requirements and certifications.

Authorized Signature _____

Date _____

Typed or printed name _____

Registration No. _____



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
18/510,801	11/16/2023	Hani Kayyali	CMD-135	8871
81177	7590	09/24/2024	EXAMINER	
Cleveland Medical Devices Inc. 4415 Euclid Ave. Ste. 500 Cleveland, OH 44103			NATNITHITHADHA, NAVIN	
			ART UNIT	PAPER NUMBER
			3791	
DATE MAILED: 09/24/2024				

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b) (Applications filed on or after May 29, 2000)

The Office has discontinued providing a Patent Term Adjustment (PTA) calculation with the Notice of Allowance.

Section 1(h)(2) of the AIA Technical Corrections Act amended 35 U.S.C. 154(b)(3)(B)(i) to eliminate the requirement that the Office provide a patent term adjustment determination with the notice of allowance. See Revisions to Patent Term Adjustment, 78 Fed. Reg. 19416, 19417 (Apr. 1, 2013). Therefore, the Office is no longer providing an initial patent term adjustment determination with the notice of allowance. The Office will continue to provide a patent term adjustment determination with the Issue Notification Letter that is mailed to applicant approximately three weeks prior to the issue date of the patent, and will include the patent term adjustment on the patent. Any request for reconsideration of the patent term adjustment determination (or reinstatement of patent term adjustment) should follow the process outlined in 37 CFR 1.705.

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

OMB Clearance and PRA Burden Statement for PTOL-85 Part B

The Paperwork Reduction Act (PRA) of 1995 requires Federal agencies to obtain Office of Management and Budget approval before requesting most types of information from the public. When OMB approves an agency request to collect information from the public, OMB (i) provides a valid OMB Control Number and expiration date for the agency to display on the instrument that will be used to collect the information and (ii) requires the agency to inform the public about the OMB Control Number's legal significance in accordance with 5 CFR 1320.5(b).

The information collected by PTOL-85 Part B is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. The United States Patent and Trademark Office (USPTO) collects the information in this record under authority of 35 U.S.C. 2. The USPTO's system of records is used to manage all applicant and owner information including name, citizenship, residence, post office address, and other information with respect to inventors and their legal representatives pertaining to the applicant's/owner's activities in connection with the invention for which a patent is sought or has been granted. The applicable Privacy Act System of Records Notice for the information collected in this form is COMMERCE/PAT-TM-7 Patent Application Files, available in the Federal Register at 78 FR 19243 (March 29, 2013).

<https://www.govinfo.gov/content/pkg/FR-2013-03-29/pdf/2013-07341.pdf>

Routine uses of the information in this record may include disclosure to:

- 1) law enforcement, in the event that the system of records indicates a violation or potential violation of law;
- 2) a federal, state, local, or international agency, in response to its request;
- 3) a contractor of the USPTO having need for the information in order to perform a contract;
- 4) the Department of Justice for determination of whether the Freedom of Information Act (FOIA) requires disclosure of the record;
- 5) a Member of Congress submitting a request involving an individual to whom the record pertains, when the individual has requested the Member's assistance with respect to the subject matter of the record;
- 6) a court, magistrate, or administrative tribunal, in the course of presenting evidence, including disclosures to opposing counsel in the course of settlement negotiations;
- 7) the Administrator, General Services Administration (GSA), or their designee, during an inspection of records conducted by GSA under authority of 44 U.S.C. 2904 and 2906, in accordance with the GSA regulations and any other relevant (i.e., GSA or Commerce) directive, where such disclosure shall not be used to make determinations about individuals;
- 8) another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c));
- 9) the Office of Personnel Management (OPM) for personnel research purposes; and
- 10) the Office of Management and Budget (OMB) for legislative coordination and clearance.

If you do not furnish the information requested on this form, the USPTO may not be able to process and/or examine your submission, which may result in termination of proceedings, abandonment of the application, and/or expiration of the patent.

Notice of Allowability	Application No. 18/510,801	Applicant(s) Kayyali et al.	
	Examiner NAVIN NATNITHITHADHA	Art Unit 3791	AIA (FITF) Status No

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to the Amendment and Remarks, filed 28 August 2024.
☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on _____.

2. ☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on _____; the restriction requirement and election have been incorporated into this action.

3. ☒ The allowed claim(s) is/are 1-20 . As a result of the allowed claim(s), you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see http://www.uspto.gov/patents/init_events/pph/index.jsp or send an inquiry to PPHfeedback@uspto.gov.

4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

Certified copies:

a) ☐ All b) ☐ Some* c) ☐ None of the:

1. ☐ Certified copies of the priority documents have been received.

2. ☐ Certified copies of the priority documents have been received in Application No. _____.

3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).

6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☐ Notice of References Cited (PTO-892)	5. ☒ Examiner's Amendment/Comment
2. ☐ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date _____.	6. ☒ Examiner's Statement of Reasons for Allowance
3. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material _____.	7. ☐ Other _____.
4. ☒ Interview Summary (PTO-413), Paper No./Mail Date. _____.	

/NAVIN NATNITHITHADHA/ Primary Examiner, Art Unit 3791	
---	--

DETAILED ACTION

Notice of Pre-AIA or AIA Status

1. The present application is being examined under the pre-AIA first to invent provisions.

Examiner's Amendment

2. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Brian M. Kolkowski on 20 September 2024.

The application has been amended as follows:

- -

18. (currently amended) The system in Claim 2, wherein the second processor of the PAP device is configured to distinguish between and calculate the severity of both obstructive apneas and central apneas of the subject during a treatment with the PAP device.

19. (currently amended) The system in Claim 10, wherein the second processor of the PAP device is configured to distinguish between and calculate the severity of both obstructive apneas and central apneas of the subject during a treatment with the PAP device.

20. (currently amended) A positive airway pressure (PAP) sleep disorder treatment system comprising:

a non-transitory computer readable medium comprising a first software, the first software adapted to be downloaded to a cell phone and executable by a first processor on the cell phone to display to a subject for viewing on the cell phone a treatment efficacy of the subject using a PAP device, the treatment efficacy based in whole or in part on a data based on one or more measure(s) of the treatment efficacy received by the first software, the cell phone comprising at least one first radio frequency wireless transceiver, the first processor, the first software when downloaded, and a display;

the PAP device with an enclosure further comprising:

a blower having an air output within the enclosure,

an airflow sensor being any type of sensor internal to the enclosure of the PAP device adapted for measuring or deriving the respiratory airflow of a subject while using the PAP device and outputting airflow sensor data,

a second processor within the enclosure adapted for receiving the airflow sensor data and for calculating the one or more measures of the treatment efficacy comprising:

i) the data of a severity of the sleep disorder symptoms of the subject,

ii) the data of usage of the PAP device by the subject, and/or

iii) the index based in whole or in part on either i) or ii) or both i) and ii),

a mask or a nasal cannula connected to the enclosure, and

at least one second radio frequency wireless transceiver within the enclosure, the
at least one second radio frequency wireless transceiver adapted for transmitting
a PAP data based in whole or part on at least one of the one or more measures of
treatment efficacy calculated by the second processor;

the non-transitory computer readable medium or a second non-transitory computer
readable medium comprising a second software adapted to be executable the first
processor on the cell phone or a third processor on a portable, wearable patient data
acquisition device comprising a pulse oximeter and an accelerometer the portable,
wearable patient data acquisition device adapted to wore on the subject's finger to
collect additional physiological data from the subject while using the PAP device for
combining with the data collected by the PAP device, the second software further adapted
to forward the additional physiological data to combine with the data from the PAP
device to determine the treatment efficacy of the subject using the PAP device; and

a remote internet site, the remote internet site adapted for receiving the PAP data or data
based on the at least one of the one or more treatment efficacy measures, related to the
subject's treatment and the treatment's efficacy in whole or part, generated by the PAP
device and transmitted via the at least one second radio frequency wireless transceiver,
and the additional physiological data collected with the portable, wearable patient
acquisition device.

--

Response to Amendment

3. According to the Amendment, filed 28 August 2024, the status of the claims is as follows:

Claim 20 is currently amended; and
Claims 1-19 are as originally filed.

Terminal Disclaimer

4. The terminal disclaimer filed on 28 August 2024 disclaiming the terminal portion of any patent granted on this application which would extend beyond the expiration date of U.S. Patent No. 11,872,029 B2 has been reviewed and is accepted. The terminal disclaimer has been recorded.

Response to Arguments

5. Applicant's arguments, see Remarks, pp. 11-21, filed 28 August 2024, with respect to the rejection of claims 1, 2, 4, 6-9, and 12-19 under pre-AIA 35 U.S.C. 103(a) as being unpatentable over Farrell et al., U.S. Patent Application Publication No. 2007/0161913 A1 ("Farrell"), in view of Geva et al., U.S. Patent Application Publication No. 2004/0073098 A1 ("Geva"), the rejection of claims 3 and 5 under pre-AIA 35 U.S.C. 103(a) as being unpatentable over Farrell, as applied to claims 2 and 4, respectively, above, further in view of Hedner et al., U.S. Patent Application Publication No. 2008/0257349 A1 ("Hedner"), and the rejection of claim 20 under pre-AIA 35 U.S.C. 103(a) as being unpatentable over Farrell in view of Lee et al., U.S. Patent Application Publication No. 2005/0061323 A1 ("Lee"), and further in view of Geva, have been fully considered, and are persuasive. Therefore, the rejections of claims 1-20 have been withdrawn.

Claim Objection

6. In an Interview, on 18 September 2024, Examiner and Applicant's Representative, Brian M. Kolkowski, agreed on amending claims 18-20 by the Examiner's Amendment above to overcome the objection of claims 18-20, and to place the Application in condition for allowance. See Examiner-Initiated Interview Summary, mailed with the present Office Action.

Reasons for Allowance

7. Claims 1-19 are allowed.

8. The following is an examiner's statement of reasons for allowance:

As to Claim 1-19, neither Farrell, Geva, Hedner, Lee nor the prior art of record teaches the positive airway pressure sleep disorder treatment system of base claim 1, including the following, in combination with all other limitations of the base claim:

a non-transitory computer readable medium comprising a first software, the first software adapted to be downloaded to a cell phone and executable by a first processor on the cell phone to display to a subject for viewing on the cell phone a treatment efficacy of the subject using a PAP device, ... the cell phone comprising at least one first radio frequency wireless transceiver, the first processor, the first software when downloaded, and a display;
the PAP device with an enclosure further comprising:

...

an airflow sensor being any type of sensor internal to the enclosure of the PAP device adapted for measuring or deriving the respiratory airflow of a subject while using the PAP device and outputting airflow sensor data,

a second processor within the enclosure adapted for receiving the airflow sensor data and for calculating the one or more measures of the treatment efficacy comprising:

- i) the data of a severity of the sleep disorder symptoms of the subject,
- ii) the data of usage of the PAP device by the subject, and/or
- iii) the index based in whole or in part on either i) or ii) or both i) and ii),

...

a remote internet site, the remote internet site adapted for receiving the PAP data or data based on the at least one of the one or more treatment efficacy measures, related to the subject's treatment and the treatment's efficacy in whole or part, generated by the PAP device and transmitted via the at least one second radio frequency wireless transceiver.

As to Claim 20, neither Farrell, Geva, Hedner, Lee nor the prior art of record teaches the positive airway pressure sleep disorder treatment system of base claim 20, including the following, in combination with all other limitations of the base claim:

a non-transitory computer readable medium comprising a first software, the first software adapted to be downloaded to a cell phone and executable by a first processor on the cell phone to display to a subject for viewing on the cell phone a treatment efficacy of the subject using a PAP device, ... the cell phone comprising at least one first radio frequency wireless transceiver, the first processor, the first software when downloaded, and a display;
the PAP device with an enclosure further comprising:

...

an airflow sensor being any type of sensor internal to the enclosure of the PAP device adapted for measuring or deriving the respiratory airflow of a subject while using the PAP device and outputting airflow sensor data,

a second processor within the enclosure adapted for receiving the airflow sensor data and for calculating the one or more measures of the treatment efficacy comprising:

- i) the data of a severity of the sleep disorder symptoms of the subject,
- ii) the data of usage of the PAP device by the subject, and/or
- iii) the index based in whole or in part on either i) or ii) or both i) and ii),

...

the non-transitory computer readable medium or a second non-transitory computer readable medium comprising a second software adapted to be executable the first processor on the cell phone or a third processor on a portable, wearable patient data acquisition device comprising a pulse oximeter and an accelerometer the portable, wearable patient data acquisition device adapted to be worn on the subject's finger to collect additional physiological data from the subject while using the PAP device for combining with the data collected by the PAP device, the second software further adapted to forward the additional physiological data to combine with the data from the PAP device to determine the treatment efficacy of the subject using the PAP device; and

a remote internet site, the remote internet site adapted for receiving the PAP data or data based on the at least one of the one or more treatment efficacy measures, related to the subject's treatment and the treatment's efficacy in whole or part, generated by the PAP device and transmitted via the at least one second radio frequency wireless transceiver, and the additional physiological data collected with the portable, wearable patient acquisition device.

9. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Conclusion

10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to NAVIN NATNITHITHADHA whose telephone number is (571)272-4732. The examiner can normally be reached Monday - Friday 6:00 am - 8:30 am & 10:30 am - 4:00 pm.

Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at <http://www.uspto.gov/interviewpractice>.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jason M Sims can be reached on 571-272-7540. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center,

Application/Control Number: 18/510,801

Page 9

Art Unit: 3791

visit: <https://patentcenter.uspto.gov>. Visit <https://www.uspto.gov/patents/apply/patent-center> for more information about Patent Center and

<https://www.uspto.gov/patents/docx> for information about filing in DOCX format. For

additional questions, contact the Electronic Business Center (EBC) at 866-217-9197

(toll-free). If you would like assistance from a USPTO Customer Service

Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

**/NAVIN NATNITHITHADHA/
Primary Examiner, Art Unit 3791
09/20/2024**